BBVA heads into its Q1 earnings call on April 30 with a sharp and sudden shift in options positioning — the standout signal in an otherwise quiet week for the Spanish lender's ADR.
Options traders turned markedly more defensive on Tuesday. The put/call ratio jumped to 0.87, well above its 20-day average of 0.19 and a z-score of 2.74 standard deviations above the norm — making it one of the most elevated defensive readings of the past year, second only to the 52-week high of 1.11. For a stock where puts have barely registered relative to calls for most of the past month, a single-day move of this magnitude is hard to ignore. The timing is the tell: the print lands the morning before the earnings release.
Short interest is not part of this story in a meaningful way. Estimated shares short declined 22% on Tuesday alone, bringing the 30-day fall to 42%. With a days-to-cover ratio of roughly 0.5 and borrowing costs running at just 0.57% annually, the lending market is wide open. Availability is loose. This is not a name where short sellers are building a structural view.
The analyst picture is similarly low-key, with one notable exception. UBS downgraded BBVA to Neutral from Buy on April 20 — a recent and relevant move from a bellwether firm. No price targets were attached to the change, so the precise valuation argument is unclear, but the direction of travel from UBS is unambiguously more cautious. The broader analyst consensus on the NYSE-listed ADR is thin and stale; the key coverage lives on the Spanish exchange. Valuation, however, has re-rated positively over the past month: the P/E multiple has expanded to 10.1x, up roughly 0.6 turns over 30 days, and the price-to-book has moved to 1.70x. BBVA is not obviously cheap nor obviously stretched at these levels. The dividend score ranks in the 84th percentile, reflecting the group's income appeal for international investors even though the US dividend data is several years out of date.
The institutional footprint is large and stable. BlackRock held 5.49% of shares as of end-March, with Capital Research close behind at 5.20% and Vanguard at 4.64%. All three added modestly in Q1. Goldman Sachs — reporting as of April 15 — added 2.8 million shares, bringing its position to 0.70%. Norges Bank, by contrast, trimmed 32.6 million shares in Q4 2025. The net ownership picture is incrementally positive into the result.
Earnings history adds context. The February 2026 full-year results were poorly received: the ADR fell 6.2% on the day and extended to a 9.1% loss over five days. The October 2025 quarterly release was far more benign, with a 0.8% one-day dip followed by a 1.9% five-day gain. That asymmetry matters — on the evidence of recent prints, a weak result tends to be punished more than a strong one is rewarded.
The options shift is therefore the central question heading into Wednesday morning. Whether the Q1 numbers can reverse the pattern from February — or confirm the caution behind UBS's downgrade — is what the market will be measuring.
See the live data behind this article on ORTEX.
Open BBVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
